GlassScriptPhysician profile
Vyannhe Vela-Ramirez
NPI 1477642643
$12,115.11
in general payments reported to CMS, 2019-2025
53 companies · $2,731 in 2025
The $2,731 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,024 · 2022: $2,269 · 2023: $1,962 · 2024: $2,129 · 2025: $2,731.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,822.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,657.44 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,614.96 | 2021-2025 | |
| Amgen INC. | $1,202.34 | 2021-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $755.86 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $590.45 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $553.22 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $539.31 | 2021-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $459.35 | 2021-2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $331.90 | 2021-2025 | Zoryve, Livalo, Seglentis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.77 | 2021-2025 | Jardiance, Ofev |
| Amarin Pharma, INC. | $302.46 | 2021-2023 | |
| Astellas Pharma US INC | $300.43 | 2021-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $239.27 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Ironwood Pharmaceuticals, INC | $222.19 | 2021-2024 | Linzess |
| Sumitomo Pharma America, INC. | $221.63 | 2024-2025 | Gemtesa |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vyannhe Vela-Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.